DK0652004T3 - Fremgangsmåder til behandling af resistente neoplasmer - Google Patents

Fremgangsmåder til behandling af resistente neoplasmer

Info

Publication number
DK0652004T3
DK0652004T3 DK94307527T DK94307527T DK0652004T3 DK 0652004 T3 DK0652004 T3 DK 0652004T3 DK 94307527 T DK94307527 T DK 94307527T DK 94307527 T DK94307527 T DK 94307527T DK 0652004 T3 DK0652004 T3 DK 0652004T3
Authority
DK
Denmark
Prior art keywords
chem
methods
treating resistant
resistant neoplasms
neoplasms
Prior art date
Application number
DK94307527T
Other languages
Danish (da)
English (en)
Inventor
Mark Alan Winter
James Jacob Starling
Srinivasan Chandrasekhar
Anne Hollins Dantzig
Robert Lee Shepard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0652004T3 publication Critical patent/DK0652004T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
DK94307527T 1993-10-15 1994-10-13 Fremgangsmåder til behandling af resistente neoplasmer DK0652004T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13767893A 1993-10-15 1993-10-15

Publications (1)

Publication Number Publication Date
DK0652004T3 true DK0652004T3 (da) 2002-09-02

Family

ID=22478575

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94307527T DK0652004T3 (da) 1993-10-15 1994-10-13 Fremgangsmåder til behandling af resistente neoplasmer

Country Status (17)

Country Link
EP (1) EP0652004B1 (de)
JP (1) JPH07149638A (de)
KR (1) KR950010891A (de)
CN (1) CN1108094A (de)
AT (1) ATE220323T1 (de)
AU (1) AU670518B2 (de)
CA (1) CA2118096A1 (de)
CZ (1) CZ253694A3 (de)
DE (1) DE69430940T2 (de)
DK (1) DK0652004T3 (de)
ES (1) ES2179063T3 (de)
HU (1) HUT71237A (de)
IL (1) IL111287A0 (de)
NO (1) NO943874L (de)
PT (1) PT652004E (de)
RU (1) RU94037233A (de)
ZA (1) ZA948025B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
MX9701359A (es) * 1994-08-22 1997-05-31 Lilly Co Eli Metodos para la inhibicion de la hiperplasia endometrial primaria.
AU688112B2 (en) * 1994-08-22 1998-03-05 Eli Lilly And Company Methods of inhibiting endometrial cancer
EP0777472A2 (de) 1994-08-31 1997-06-11 Eli Lilly And Company Verfahren zur identifizierung und behandlung von resistenten tumoren
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
ZA961564B (en) * 1995-02-28 1997-08-27 Lilly Co Eli Methods of inhibiting ovarian cancer.
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
WO1997017069A1 (en) * 1995-11-07 1997-05-15 Eli Lilly And Company Methods for treating resistant tumors
ID15917A (id) * 1996-01-29 1997-08-21 Lilly Co Eli Metode untuk menghambat tumor usus besar
US5670523A (en) * 1996-01-29 1997-09-23 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
PL328127A1 (en) * 1996-01-29 1999-01-18 Lilly Co Eli Methods of inhibiting aponeurotic muscular fibromatosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
CZ300261B6 (cs) * 1996-10-30 2009-04-01 Eli Lilly And Company Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
WO2002089801A1 (en) * 2001-05-10 2002-11-14 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostave cancer
US7425565B2 (en) 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
EP0652004A1 (de) 1995-05-10
RU94037233A (ru) 1996-08-27
DE69430940D1 (de) 2002-08-14
HUT71237A (en) 1995-11-28
ZA948025B (en) 1996-04-15
PT652004E (pt) 2002-10-31
CN1108094A (zh) 1995-09-13
NO943874L (no) 1995-04-18
HU9402961D0 (en) 1995-02-28
CA2118096A1 (en) 1995-04-16
JPH07149638A (ja) 1995-06-13
NO943874D0 (no) 1994-10-13
DE69430940T2 (de) 2003-04-03
ES2179063T3 (es) 2003-01-16
AU670518B2 (en) 1996-07-18
AU7578694A (en) 1995-05-04
IL111287A0 (en) 1994-12-29
KR950010891A (ko) 1995-05-15
CZ253694A3 (en) 1995-05-17
ATE220323T1 (de) 2002-07-15
EP0652004B1 (de) 2002-07-10

Similar Documents

Publication Publication Date Title
DK0664126T3 (da) Hæmning af trombin
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
ATE150307T1 (de) Hemmung von seborrhoe und akne
PT652004E (pt) Metodos para tratar neoplasmas resistentes
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
ATE200623T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der primären endometriumhyperplasie